Published in J Clin Psychopharmacol on April 01, 1992
PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLD. Drugs Future (2009) 1.02
A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther (1981) 69.83
A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med (2001) 9.98
Drug therapy. Clinical Pharmacokinetics (first of two parts). N Engl J Med (1975) 7.60
Antibiotic susceptibility patterns as aids in classification and characterization of gram-negative anaerobic bacilli. J Bacteriol (1967) 5.67
Lincomycin: activity against anaerobes and effect on normal human fecal flora. Antimicrob Agents Chemother (Bethesda) (1965) 3.29
Metabolism of reduced methylated sulfur compounds in anaerobic sediments and by a pure culture of an estuarine methanogen. Appl Environ Microbiol (1986) 3.25
Clinical pharmacokinetics (second of two parts). N Engl J Med (1975) 3.17
Use of benzodiazepines in anxiety disorders. N Engl J Med (1993) 3.12
Drug therapy: drug disposition in old age. N Engl J Med (1982) 3.04
Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet (2000) 2.94
Midazolam: pharmacology and uses. Anesthesiology (1985) 2.89
Selenate reduction to elemental selenium by anaerobic bacteria in sediments and culture: biogeochemical significance of a novel, sulfate-independent respiration. Appl Environ Microbiol (1989) 2.74
Sensitivity to triazolam in the elderly. N Engl J Med (1991) 2.73
Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med (1981) 2.68
Approval of new drugs in the United States. Comparison with the United Kingdom, Germany, and Japan. JAMA (1996) 2.53
Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol (1980) 2.48
Antidepressants and cancer: cause for concern? J Clin Psychopharmacol (1993) 2.43
Antibacterial sensitivity of Bifidobacterium (Lactobacillus bifidus). J Bacteriol (1967) 2.21
Intramuscular injection of drugs. N Engl J Med (1976) 2.20
Impairment of antipyrine clearance in humans by propranolol. Circulation (1978) 2.18
Diazepam disposition determinants. Clin Pharmacol Ther (1980) 2.16
Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology (1984) 2.14
Isolation, Growth, and Metabolism of an Obligately Anaerobic, Selenate-Respiring Bacterium, Strain SES-3. Appl Environ Microbiol (1994) 2.13
Toxicity of high-dose flurazepam in the elderly. Clin Pharmacol Ther (1977) 2.05
Body site colonization in patients with community-associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections. Clin Microbiol Infect (2009) 2.04
Arsenic(III) fuels anoxygenic photosynthesis in hot spring biofilms from Mono Lake, California. Science (2008) 1.98
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos (2000) 1.87
Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol (1996) 1.86
Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry (1990) 1.84
Automated gas chromatography for studies of midazolam pharmacokinetics. Anesthesiology (1981) 1.78
Reversible alterations in immunoregulatory T cells in smoking. Analysis by monoclonal antibodies and flow cytometry. Chest (1982) 1.76
Pulsed-field gel electrophoresis and ribotype profiles of clinical and environmental Vibrio vulnificus isolates. Appl Environ Microbiol (1996) 1.72
Ataxia and slurred speech after artesunate treatment for falciparum malaria. N Engl J Med (1997) 1.72
Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. Br J Clin Pharmacol (1978) 1.65
From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin Pharmacol Ther (2015) 1.59
Clinical pharmacokinetics of quinidine. Clin Pharmacokinet (1980) 1.59
Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol (1981) 1.59
White paper on herbal products. American College of Clinical Pharmacy. Pharmacotherapy (2000) 1.58
Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry (1998) 1.56
Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program. Drugs (1974) 1.54
Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. JAMA (1973) 1.54
Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations. Drug Metab Rev (1978) 1.54
Degradation of methyl bromide by methanotrophic bacteria in cell suspensions and soils. Appl Environ Microbiol (1994) 1.54
Bacterial oxidation of methyl bromide in fumigated agricultural soils. Appl Environ Microbiol (1997) 1.53
Dissimilatory arsenate and sulfate reduction in sediments of two hypersaline, arsenic-rich soda lakes: Mono and Searles Lakes, California. Appl Environ Microbiol (2006) 1.52
Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther (2001) 1.52
Differential actions of chlordiazepoxide and oxazepam on hostility. Arch Gen Psychiatry (1968) 1.50
Patients with methicillin-resistant Staphylococcus aureus infection: twenty-first century lepers. J Hosp Infect (2010) 1.48
Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos (2001) 1.47
Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther (1980) 1.47
Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord (1989) 1.44
Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther (1994) 1.44
Clinical toxicity of furosemide in hospitalized patients. A report from the Boston Collaborative Drug Surveillance Program. Am Heart J (1977) 1.43
Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med (1980) 1.42
A retrospective study of children's perceptions of participation as clinical research subjects in a minimal risk study. J Dev Behav Pediatr (2001) 1.42
Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol (1997) 1.42
Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Ther (2000) 1.41
Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry (1993) 1.41
Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam. J Chromatogr (1978) 1.41
Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Am J Psychiatry (2000) 1.40
Drug transporters in psychopharmacology--are they important? J Clin Psychopharmacol (2000) 1.40
In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. Br J Anaesth (1983) 1.39
Toward a greater understanding of the parents of the mentally retarded child. J Pediatr (1968) 1.39
MAOIs and hypertension. J Clin Psychopharmacol (1992) 1.39
What is the relevance of antiretroviral therapy that does not include protease inhibitors? Clin Infect Dis (1998) 1.39
Drug therapy. Current status of benzodiazepines. N Engl J Med (1983) 1.39
Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol (1996) 1.39
Estimating the cost of nosocomial candidemia in the united states. Clin Infect Dis (2001) 1.38
Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci (1979) 1.37
Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. Cardiology (1984) 1.37
Effect of midazolam infusion and flumazenil administration on epinephrine arrhythmogenicity in dogs anesthetized with halothane. Anesthesiology (1993) 1.37
Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry (1990) 1.35
Lorazepam kinetics in the elderly. Clin Pharmacol Ther (1979) 1.35
Pharmacokinetic and clinical implications of quinidine protein binding. J Pharm Sci (1979) 1.34
The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Clin Microbiol Infect (2012) 1.34
Absorption and disposition of chlordiazepoxide in young and elderly male volunteers. J Clin Pharmacol (1978) 1.33
Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther (1999) 1.32
Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet (1981) 1.31
Kinetics of intravenous and intramuscular morphine. Clin Pharmacol Ther (1978) 1.29